Dogwood Therapeutics Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Dogwood Therapeutics stock has a target of 10, which predicts a 108.38% increase from the current stock price of 4.8.

Price Target: $10 (+108.38%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$10	$10	$10	$10
Change	+108.38%	+108.38%	+108.38%	+108.38%

* Price targets were last updated on Apr 23, 2025.

Analyst Ratings

According to 1 stock analyst, the rating for Dogwood Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jun '25	Jul '25
Strong Buy	1	1
Buy	0	0
Hold	0	0
Sell	0	0
Strong Sell	0	0
Total	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Sean Lee HC Wainwright & Co.	HC Wainwright & Co.	Hold → Strong Buy Upgrades $10	Hold → Strong Buy	Upgrades	$10	+108.38%	Apr 23, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

from 34.31M

Revenue Next Year

n/a

EPS This Year

-9.77

from -12.52

EPS Next Year

-4.64

from -9.77

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027	FY 2028	FY 2029
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027	Dec 31, 2028	Dec 31, 2029
Revenue	-	-	-	18.81M	34.31M
Revenue Growth	-	-	-	-	82.41%	-	-	-
EPS	-52.50	-48.00	-27.66	-7.05	-12.52	-9.77	-4.64	-4.12
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	5	5	5

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	n/a	n/a	n/a
Avg	n/a	n/a	n/a
Low	n/a	n/a	n/a

Revenue Growth

Revenue Growth	2025	2026	2027
High	-	-	-
Avg	-	-	-
Low	-	-	-

EPS Forecast

EPS	2025	2026	2027
High	-3.71	-2.99	-3.73
Avg	-9.77	-4.64	-4.12
Low	-12.64	-5.56	-4.36

EPS Growth

EPS Growth	2025	2026	2027
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.